In Reply We thank Blumenthal and colleagues for their thoughtful comments regarding our Editor’s Note.3 They have correctly identified that the 18 cancer drugs examined in the research letter by Rupp et al1 were not all approved via the accelerated pathway as stated; in fact, many of these cancer drugs were regular approvals. We thank them for pointing out this error and appreciate this opportunity to respond to their other comments.
Bauer SR, Redberg RF. Setting the Record Straight on FDA Approvals in Oncology—Reply. JAMA Intern Med. 2017;177(8):1223. doi:https://doi.org/10.1001/jamainternmed.2017.2254
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: